Serous borderline tumor of the paratestis: a report of seven cases.
McClure RF, Keeney GL, Sebo TJ, Cheville JC.
Am J Surg Pathol. 2001 Mar;25(3):373-8. doi: 10.1097/00000478-200103000-00012.
The role of human epididymis protein 4 as a biomarker in gynecologic malignancies.
Plotti F, Scaletta G, Terranova C, Montera R, De Cicco Nardone C, Luvero D, Rossini G, Gatti A, Schirò T, Moncelli M, Guzzo F, Angioli R.
Minerva Ginecol. 2019 Feb;71(1):36-43. doi: 10.23736/S0026-4784.18.04328-9. Epub 2018 Oct 11.
Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis.
Macedo AC, da Rosa MI, Lumertz S, Medeiros LR.
Int J Gynecol Cancer. 2014 Sep;24(7):1222-31. doi: 10.1097/IGC.0000000000000192.
Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B, Fuksiewicz M, Sobiczewski P, Spiewankiewicz B, Jonska-Gmyrek J, Skrzypczak M, Kowalska M.
Eur J Obstet Gynecol Reprod Biol. 2015 Nov;194:141-6. doi: 10.1016/j.ejogrb.2015.09.008. Epub 2015 Sep 12.
Comparison of Human Epididymis Protein 4, Cancer Antigen 125, and Ultrasound Prediction Model in Differentiating Benign from Malignant Adnexal Masses.
Bahadur A, Bhattacharya N, Mundhra R, Khoiwal K, Chawla L, Singh R, Naithani M, Kishore S.
J Midlife Health. 2023 Jul-Sep;14(3):176-183. doi: 10.4103/jmh.jmh_77_23. Epub 2023 Dec 30.
Miscellaneous rare paratesticular tumors.
Henley JD, Ferry J, Ulbright TM.
Semin Diagn Pathol. 2000 Nov;17(4):319-39.
Evaluation of Ovarian Tumors with Multidetector Computed Tomography and Tumor Markers: Differentiation of Stage I Serous Borderline Tumors and Stage I Serous Malignant Tumors Presenting as Solid-Cystic Mass.
Yu XP, Liu Y, Jiao JW, Yang HJ, Wang RJ, Zhang S.
Med Sci Monit. 2020 Aug 17;26:e924497. doi: 10.12659/MSM.924497.
Ovarian Serous Cystadenoma of the Epididymis: A Case Report.
Pierce DP, Chen B, Taylor L.
Cureus. 2023 Oct 12;15(10):e46886. doi: 10.7759/cureus.46886. eCollection 2023 Oct.
Comparison of Risk of Ovarian Malignancy Algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early-stage ovarian cancer according to imaging tumor subtypes.
Lee YJ, Kim YM, Kang JS, Nam SH, Kim DY, Kim YT.
Oncol Lett. 2020 Jul;20(1):931-938. doi: 10.3892/ol.2020.11629. Epub 2020 May 14.
Appendageal tumors and tumor-like lesions of the testis and paratestis: a 32-year experience at a single institution.
Al-Obaidy KI, Alruwaii FI, Ulbright TM, Idrees MT.
Hum Pathol. 2020 Sep;103:25-33. doi: 10.1016/j.humpath.2020.06.006. Epub 2020 Jun 30.
